Seeing Is Believing
Currently out of the existing stock ratings of Katherine Breedis, 5 are a BUY (100%).
Analyst Katherine Breedis, carries an average stock price target met ratio of 50% that have a potential upside of 40.48% achieved within 1465 days. Previously, Katherine Breedis worked at STIFEL.
Katherine Breedis’s has documented 10 price targets and ratings displayed on 2 stocks. The coverage was on the Healthcare sector.
Most recent stock forecast was given on VYGR, Voyager Therapeutics at 27-Jul-2017.
Analyst best performing recommendations are on GILD (GILEAD SCIENCES).
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy
$135
$12.19 (9.93%)
$125
15 days ago
(07-Oct-2025)
15/17 (88.24%)
$16.75 (14.16%)
1220
Buy
$145
$22.19 (18.07%)
$130
1 months 7 days ago
(15-Sep-2025)
4/6 (66.67%)
$34.14 (30.80%)
164
Buy
$133
$10.19 (8.30%)
2 months 28 days ago
(24-Jul-2025)
0/1 (0%)
$17.6 (15.25%)
Hold
$95
$-27.81 (-22.64%)
$89
4 months 12 days ago
(10-Jun-2025)
65/76 (85.53%)
$-12.78 (-11.86%)
1689
Buy
$117
$-5.81 (-4.73%)
$100
5 months 18 days ago
(04-May-2025)
13/13 (100%)
$15.62 (15.41%)
991
What Year was the first public recommendation made by Katherine Breedis?